Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Depakote(R) Delayed Release Tablets
Date:7/30/2008

DETROIT, July 30 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (Amex: CPD) announced today, that it has launched divalproex sodium delayed release tablets on behalf of Sun Pharmaceutical Industries Ltd. (Sun Pharma). Sun Pharma recently received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for generic Depakote(R) delayed release tablets.

Divalproex sodium delayed release tablets are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures, as sole and adjunct therapy for patients with simple and complex absence seizures, for the treatment of the manic episodes associated with bipolar disorders, as well as for prophylaxis of migraine headaches. These generic versions of divalproex sodium delayed release 125 mg, 250 mg, and 500 mg (valproic acid activity) tablets are bioequivalent to Depakote(R) delayed release tablets distributed by Abbott Laboratories. According to IMS Data, Depakote(R) had US. sales of approximately $750 million for the 12-month period ended March 2008.

Depakote(R) is a registered trademark of Abbott Laboratories.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward- looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Elavil(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
3. Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008
4. Caraco Pharmaceutical Laboratories Ltd. Wins Summary Judgment on Generic Ultracet(R)
5. Caraco Pharmaceutical Laboratories Ltd. To Market Generic Ethyol(R)
6. Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
11. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , ... February 11, 2016 , ... The president released ... Military Health System but would shift more of the cost burden to military beneficiaries. ... plan laid out in the defense budget as including limited quantifiable benefit fixes mixed ...
(Date:2/11/2016)... Texas (PRWEB) , ... February 11, 2016 , ... ... plastic surgery, dermatology and women’s health, is pleased to announce the promotions of ... Development Partners sales team, Steve Catone to executive vice president of North American ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... call for nominations seeking candidates for the Board of Commissioners. Individuals interested in ... skills and experience with diversity of clinical practice settings and across allied health ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... commencement of a master charity program created to assist the people of their ... working closely with nonprofit organizations and community leaders. Their hope is to bring ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... their ongoing community involvement program, introduces a new charity campaign to raise funds ... are now being accepted at https://donate.rmhc.org/ . , Ronald McDonald House (RMH) ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... ALEX , has taken Kickstarter by storm, crowdfunding over $60,000 – or 120% of its original ... to be delivered to backers starting May of this year. ... ... ... Created by NAMU, a team of biomedical engineers out of ...
(Date:2/11/2016)... ROLLING MEADOWS , Ill. and INDIANAPOLIS ... major milestone for many young people, but for those ... demanding. Not only do these students juggle class schedules, ... challenges of living with type 1 diabetes. On top ... the first time. Diabetes Scholars Foundation ...
(Date:2/11/2016)... Feb. 11, 2016  AbbVie, a global biopharmaceutical ... Scholarship, designed to provide financial support for exceptional ... pursue higher education goals. Fifteen scholars will be ... school year. The AbbVie Rheumatology Scholarship is currently ... vice president, corporate social responsibility, brand and communications, ...
Breaking Medicine Technology: